Medindia

X

NxStage(R) Announces New Vice President and General Manager, Critical Care Therapies

Wednesday, February 24, 2010 General News J E 4
Advertisement


LAWRENCE, Mass., Feb. 23 NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Elise A. Tordella has joined the Company as Vice President and General Manager of Critical Care Therapies. In this position, Ms. Tordella will oversee NxStage's strategic growth initiatives to provide quality continuous renal replacement therapy (CRRT) solutions to the estimated U.S. $100 million critical care market opportunity.

"In addition to pioneering the home dialysis market with the System One, NxStage is an established leader in the critical care market, achieving an estimated 25 percent U.S. market share," said Joseph E. Turk, Senior Vice President, Commercial Operations, NxStage Medical. "The critical care market is a strategic component to our overall growth and profitability. We are delighted to have Elise Tordella on board. Her wealth of experience in sales and marketing for the medical device industry globally will drive efforts to deepen our penetration in the critical care dialysis market."

"I am excited to join NxStage and be a part of a company that is making significant contributions to the dialysis community, specifically critical care patients," said Elise Tordella. "I look forward to using my knowledge and experience in the medical device industry to help foster NxStage's continued growth in the critical care market and further enhance our value proposition to customers."

Tordella brings to NxStage more than 25 years of experience in multiple segments of the medical device industry, including renal, cardiology and general hospital products. Most recently, Tordella served as the Vice President of Global Marketing for Patient Care at Covidien, a company that manufactures, distributes and services medical devices, pharmaceuticals and medical supplies. Additionally, in her 18 year career at Covidien, Tordella was U.S. President for the Ludlow Division and has held a variety of marketing, product development and general management positions with the company.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of End Stage Renal Disease (ESRD) and acute kidney failure. For more information on NxStage and its products, please visit NxStage's website at www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact Kristen Sheppard NxStage Medical, Inc. ir@nxstage.com 978-332-5923 Media Contact Jane Hauser or Jasmine Fielding Schwartz Communications, Inc. nxstage@schwartz-pr.com 781-684-0770

SOURCE NxStage Medical, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
MAP Pharmaceuticals to Present at Upcoming Healthc...
S
ISTA Pharmaceuticals Reports Fourth Quarter and Fu...